April 30, 2021 Columns by Ed Tobias What Do the Oscars and Our COVID-19 Response Have in Common? What could the Academy Awards and COVID-19 possibly have in common for people with disabilities? Stay tuned, and I’ll tell you. First, the Academy Awards. The documentary “Crip Camp,” about a summer camp for young adults with disabilities, was up for an Oscar. Its co-director and co-star, Jim LeBrecht,…
June 25, 2019 Columns by Ed Tobias What’s Your Doctor Writing About You? Ask to Read the Notes I’ve been living with MS for nearly 39 years and I’ve never seen the notes my neurologist has written during my office visits. My neuro did hand me a thick folder of notes several years ago. It had material dating back to my diagnosis in 1980, but when we…
May 31, 2019 Columns by John Connor A Wee Trip ā But Not Like in the Past I looked at the road, then west to the horizon. It was the Trans-Canada Highway. I was standing just outside Halifax, Nova Scotia. A 23-year-old intending to hitchhike the length of the Trans-Canadian to Vancouver. I’m English but knew this was a rite of passage for young Canadians.
April 6, 2017 News by Patricia Silva, PhD ‘Adequate and Rapid Delivery’ of Ocrevus Expected, Says Genentech Director in Interview Ocrevus (ocrelizumab),Ā now approved for both relapsing and primary progressive multiple sclerosis (MS), is expected to become available in the coming week. While patients and neurologists are waiting, Multiple Sclerosis News Today spoke to Genentech about the treatment’s approval, future research plans, and what patients can expect in terms…
April 4, 2017 News by Patricia Silva, PhD Transcript of Interview with Dr. Robert Lisak, a Neurologist and MS Expert, About Ocrevus Here is a transcript of the Multiple Sclerosis News Today interview about Ocrevus (ocrelizumab) with Dr. Robert Lisak of the Consortium of Multiple Sclerosis Centers (CMSC). Lisak, a professor of neurology and of immunology and microbiology at Wayne State University School of Medicine, is aĀ former…
April 4, 2017 News by Patricia Silva, PhD Ocrevus Holds Promise, But Needs to Prove Itself in ‘Long Term,’ Says Dr. Robert Lisak with CMSC Interest inĀ Ocrevus (ocrelizumab), the first FDA-approved treatment for bothĀ relapsing and primary progressive multiple sclerosis, isĀ running high among patients and the organization representing them ā as, arguably, are expectations ofĀ its use. But how do physicians involved in MS care view the newcomer? Dr. Robert Lisak (Photo…
April 3, 2017 News by Patricia Silva, PhD What Every MS Patient Should Know About Ocrevus and Its Use With the recent approval of Ocrevus (ocrelizumab) for both primary progressive and relapsing multiple sclerosis (MS), interest in the medication is peaking.Ā To helpĀ readers of Multiple Sclerosis News TodayĀ better understandĀ this new medication and how it works, as well issues dealingĀ with access, use, and potential side effects, here is aĀ summary…